A Future Where a One-Time Genetic Treatment Cures a Condition for Life...

Why It Matters

The idea signals a potential shift in how gene therapies could be financed—prioritizing recurring revenue for developers—but raises serious ethical, legal and access concerns that could prompt regulatory scrutiny and public backlash. How firms balance sustainable business models with patient rights and affordability will shape adoption and policy for next‑generation genetic medicines.

Summary

An executive at Lily publicly proposed a subscription-style pricing model for one-time genetic treatments where patients receive a lifelong cure—such as a PCSK9 liver edit that permanently lowers LDL—but then pay an annual fee in perpetuity. The pitch framed the procedure as free upfront with ongoing deposits to the company while the therapy remains effective. Critics in the clip likened the approach to indentured servitude, posing a provocative hypothetical about epigenetic age reversal that would lock recipients into lifetime payments. The exchange underscored both the commercial appeal and the moral unease around monetizing durable or permanent biomedical interventions.

Original Description

...but you pay a subscription fee every year to keep receiving the benefit.

Healthcare innovation or healthcare-as-a-service?

Where do you draw the line?